ATE364083T1 - Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren - Google Patents

Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren

Info

Publication number
ATE364083T1
ATE364083T1 AT94917653T AT94917653T ATE364083T1 AT E364083 T1 ATE364083 T1 AT E364083T1 AT 94917653 T AT94917653 T AT 94917653T AT 94917653 T AT94917653 T AT 94917653T AT E364083 T1 ATE364083 T1 AT E364083T1
Authority
AT
Austria
Prior art keywords
polypeptides
fragment
helicobacter
compositions
nucleic acids
Prior art date
Application number
AT94917653T
Other languages
English (en)
Inventor
Agnes Labigne
Sebastien Suerbaum
Richard Ferrero
Jean-Michel Thiberge
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE364083T1 publication Critical patent/ATE364083T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
AT94917653T 1993-05-19 1994-05-19 Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren ATE364083T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93401309 1993-05-19
PCT/EP1993/003259 WO1995014093A1 (en) 1993-05-19 1993-11-19 Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides

Publications (1)

Publication Number Publication Date
ATE364083T1 true ATE364083T1 (de) 2007-06-15

Family

ID=26070083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917653T ATE364083T1 (de) 1993-05-19 1994-05-19 Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren

Country Status (11)

Country Link
US (1) US6248330B1 (de)
EP (1) EP0703981B1 (de)
JP (4) JPH08509873A (de)
AT (1) ATE364083T1 (de)
AU (1) AU689779B2 (de)
CA (1) CA2144307C (de)
DE (1) DE69434985T2 (de)
DK (1) DK0703981T3 (de)
ES (1) ES2288753T3 (de)
SG (1) SG52480A1 (de)
WO (2) WO1995014093A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509873A (ja) 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US5874405A (en) * 1994-12-16 1999-02-23 Birnbaum; Gary Heat shock protein peptides that share sequences with cyclic nucleotide phosphodiesterase and methods for modulating autoimmune central nervous system disease
CA2217496A1 (en) * 1995-04-21 1996-10-24 Csl Limited Protective helicobacter antigens
DE69637947D1 (de) * 1995-04-28 2009-07-23 Merieux Oravax Snc Multimerer, rekombinanter urease impfstoff
AU5693496A (en) * 1995-05-02 1996-11-21 Institut National De La Sante Et De La Recherche Medicale Immunogenic compositions against helicobacter infection, pol ypeptides for use in the compositions, and nucleic acid sequ ences encoding said polypeptides
BR9611623A (pt) * 1995-11-30 1999-12-28 Daratech Pty Ltd Composição de vacina e processo para a profilaxia ou tratamento de infecção em um animal ou pássaro por lawsonia intracelularis ou microorganismo relacionado, molécula de ácido nucleico isolada, e, vacina genética.
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
DE69737413T2 (de) * 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville Bakterioferritin aus helicobacter pylori
DE19630390A1 (de) * 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
EP0835928A1 (de) * 1996-10-11 1998-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Helicobacter Pylori Lebendimpfstoff
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
JP3430853B2 (ja) 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
CA2351110A1 (en) * 2000-07-17 2002-01-17 Akzo Nobel N.V. Helicobacter felis vaccine
GB0021757D0 (en) * 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
NZ538284A (en) 2002-07-18 2008-04-30 Helix Biopharma Corp Use of urease and targeting molecule for inhibiting cancer cell growth
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US7790143B2 (en) 2005-06-16 2010-09-07 Universiteit Gent Vaccines for immunization against helicobacter
ATE516817T1 (de) * 2005-06-16 2011-08-15 Univ Gent Impfstoffe zur immunisierung gegen helicobacter
RU2689689C2 (ru) 2015-01-23 2019-05-28 Хеликс Байофарма Корпорейшн Конъюгаты антитело-уреаза для терапевтических целей
WO2023118394A1 (en) * 2021-12-23 2023-06-29 Intervet International B.V. Dna vaccine against leishmaniasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
GB8928625D0 (en) * 1989-12-19 1990-02-21 3I Res Expl Ltd H.pylori dna probes
US5262156A (en) * 1991-08-12 1993-11-16 Hycor Biomedical, Inc. Antigenic compositions and their use for the detection of Helicobacter pylori
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
CA2117490C (en) 1992-02-26 2009-01-06 Timothy L. Cover Purified vacuolating toxin from helicobacter pylori and methods to use same
CA2383007A1 (en) * 1992-03-02 1993-09-16 Chiron S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
WO1994004030A1 (en) * 1992-08-26 1994-03-03 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury
WO1994006474A1 (en) * 1992-09-16 1994-03-31 Galagen Inc. ANTIBODY TREATMENT OF $i(HELICOBACTER PYLORI)
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
JPH08509873A (ja) 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
ATE244578T1 (de) 1993-07-27 2003-07-15 Csl Ltd Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
AR003125A1 (es) 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
SK165197A3 (en) 1995-06-07 1999-01-11 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics

Also Published As

Publication number Publication date
CA2144307C (en) 2008-09-02
JPH08510120A (ja) 1996-10-29
JPH08509873A (ja) 1996-10-22
EP0703981A1 (de) 1996-04-03
ES2288753T3 (es) 2008-01-16
WO1994026901A1 (en) 1994-11-24
DK0703981T3 (da) 2007-10-08
DE69434985D1 (de) 2007-07-19
AU6929094A (en) 1994-12-12
CA2144307A1 (en) 1994-11-24
US6248330B1 (en) 2001-06-19
JP2008086316A (ja) 2008-04-17
WO1995014093A1 (en) 1995-05-26
JP2004337170A (ja) 2004-12-02
EP0703981B1 (de) 2007-06-06
JP3955317B2 (ja) 2007-08-08
AU689779B2 (en) 1998-04-09
SG52480A1 (en) 1998-09-28
DE69434985T2 (de) 2008-02-21

Similar Documents

Publication Publication Date Title
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
EA199800973A1 (ru) Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение
DE58906121D1 (de) Rekombinantes Vaccinia-Virus MVA.
AU539535B2 (en) Recombinant dna molecules
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
DK179290D0 (da) Rekombinante cmv-neutraliserende proteiner
DK0431541T3 (da) Toxoplasma gondii-antigener, deres fremstilling og deres anvendelse
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
ATE122394T1 (de) Pankreatische isletzellen-antigene, erhalten durch molekulare klonierung.
MY110899A (en) Dengue virus
DE68924464T2 (de) Interferon-gamma bindende Proteine.
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
GR3003754T3 (de)
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
SE8800981A (sv) A recombinant fusion protein, its use and a recombinant vector
ATE122096T1 (de) Von babesia abgeleitete antigene und polypeptide (12d3-antigen).
TH43863A (th) แอนติเจนแบคทีเรียและส่วนประกอบวัคซีน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0703981

Country of ref document: EP

REN Ceased due to non-payment of the annual fee